These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 21450086

  • 1. Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study).
    Jongen PJ, Hengstman G, Hupperts R, Schrijver H, Gilhuis J, Vliegen JH, Hoogervorst E, van Huizen M, van Munster E, Samijn J, de Schryver E, Siepman T, Tonk M, Zandbergen E, ten Holter J, van der Kruijk R, Borm G.
    BMC Neurol; 2011 Mar 30; 11():40. PubMed ID: 21450086
    [Abstract] [Full Text] [Related]

  • 2. Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).
    Jongen PJ, Lemmens WA, Hoogervorst EL, Donders R.
    Health Qual Life Outcomes; 2017 Mar 14; 15(1):50. PubMed ID: 28292329
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A prospective web-based patient-centred interactive study of long-term disabilities, disabilities perception and health-related quality of life in patients with multiple sclerosis in The Netherlands: the Dutch Multiple Sclerosis Study protocol.
    Jongen PJ, Heerings M, Lemmens WA, Donders R, van der Zande A, van Noort E, Kool A.
    BMC Neurol; 2015 Aug 04; 15():128. PubMed ID: 26238866
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2014 Jul 26; (7):CD009333. PubMed ID: 25062935
    [Abstract] [Full Text] [Related]

  • 7. Adherence to multiple sclerosis disease-modifying therapies in Ontario is low.
    Wong J, Gomes T, Mamdani M, Manno M, O'Connor PW.
    Can J Neurol Sci; 2011 May 26; 38(3):429-33. PubMed ID: 21515501
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi-centre study.
    Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, Speck J, FOCUS study group.
    Health Qual Life Outcomes; 2010 Nov 15; 8():133. PubMed ID: 21078142
    [Abstract] [Full Text] [Related]

  • 9. Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.
    La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.
    Cochrane Database Syst Rev; 2016 Nov 24; 11(11):CD009333. PubMed ID: 27880972
    [Abstract] [Full Text] [Related]

  • 10. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J, So TY.
    Drugs; 2012 Jun 18; 72(9):1195-211. PubMed ID: 22642799
    [Abstract] [Full Text] [Related]

  • 11. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT, Arndt N, Roman C, Geremakis C, Mendoza JP, Su R, Makin C, Avila RL, Vignos MC.
    Mult Scler Relat Disord; 2021 Jun 18; 51():102935. PubMed ID: 33882426
    [Abstract] [Full Text] [Related]

  • 12. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
    Ferraro D, Camera V, Baldi E, Vacchiano V, Curti E, Guareschi A, Malagù S, Montepietra S, Strumia S, Santangelo M, Caniatti L, Foschi M, Lugaresi A, Granella F, Pesci I, Motti L, Neri W, Immovilli P, Montanari E, Vitetta F, Simone AM, Sola P.
    Curr Med Res Opin; 2018 Oct 18; 34(10):1803-1807. PubMed ID: 29526118
    [Abstract] [Full Text] [Related]

  • 13. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis.
    Carter NJ, Keating GM.
    Drugs; 2010 Aug 20; 70(12):1545-77. PubMed ID: 20687620
    [Abstract] [Full Text] [Related]

  • 14. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
    Meca-Lallana JE, de Mingo-Casado P, Amorin-Díaz M, Martínez-Navarro ML, Barreiro AF.
    Clin Ther; 2010 Jun 20; 32(6):1061-6. PubMed ID: 20637960
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E, Giuliani G, Solari A, Simi S, Minozzi S, Di Pietrantonj C, Galea I.
    Cochrane Database Syst Rev; 2011 Oct 05; (10):CD007621. PubMed ID: 21975773
    [Abstract] [Full Text] [Related]

  • 16. Use of glatiramer acetate between 2010-2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients.
    Zecca C, Disanto G, Sacco R, Riccitelli GC, Gobbi C.
    BMC Neurol; 2019 Jul 12; 19(1):159. PubMed ID: 31299922
    [Abstract] [Full Text] [Related]

  • 17. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ, Figgitt DP.
    CNS Drugs; 2004 Jul 12; 18(6):379-96. PubMed ID: 15089110
    [Abstract] [Full Text] [Related]

  • 18. Satisfaction and practicality of a prefilled glatiramer acetate pen in relapsing-remitting multiple sclerosis patients.
    Schreiber H, Hipp J, Roßnagel F, Moritz C.
    Neurodegener Dis Manag; 2023 Oct 12; 13(5):281-288. PubMed ID: 37909320
    [Abstract] [Full Text] [Related]

  • 19. Fatigue and health-related quality of life in relapsing-remitting multiple sclerosis after 2 years glatiramer acetate treatment are predicted by changes at 6 months: an observational multi-center study.
    Jongen PJ, Lehnick D, Koeman J, Frequin S, Heersema D, Kornips B, Schyns-Soeterboek A, Visser LH, Schiphof P, Valkenburg A, Hiel J, FOCUS Extension Study Group.
    J Neurol; 2014 Aug 12; 261(8):1469-76. PubMed ID: 24792727
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L, Guo S, Kinter E, Fay M.
    J Med Econ; 2016 Jul 12; 19(7):684-95. PubMed ID: 26947984
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.